FOLD (Amicus Therapeutics) Short-Term Debt to Capital

The price history on the Amicus Therapeutics (FOLD) chart demonstrates the dynamics of an asset currently valued at 0.00. The business specializes in therapies for rare genetic pathologies, relying on patent protection and patient acquisition rates. Amicus Therapeutics minimizes capital expenditures by outsourcing drug manufacturing to third-party contractors and is pursuing global sales expansion in Europe and the US to achieve profitability.

To objectively assess the issuer's financial stability, it is critical to analyze the ratio of short-term liabilities (over one year) to equity, as an increase in this coefficient amid high Fed rates raises debt service costs. This chart of short-term debt to equity allows for the tracking of liquidity risks, which is particularly significant for Amicus Therapeutics (FOLD), as the company invests in costly R&D and talent retention through stock option programs.